Spago Nanomedical’s unique nanoparticles are designed to accumulate specifically in tumors utilizing the enhanced permeability and retention (EPR) effect.
Early and correct diagnosis is essential for treatment efficiency and long term survival of cancer patients. MRI is recognized as one of the best methods for accurate diagnosis of tumors but utility of the technique is limited as the contrast agents that are needed to enhance the MRI signal are not tumor selective and provide only sub-optimal imaging signal.
Spago Nanomedical’s proprietary nanomaterial SpagoPix is a tumor selective MRI contrast agent which has shown excellent contrast between tumors and surrounding tissue in preclinical studies.
The tumor selectivity of SpagoPix has been termed “a game changer” by independent radiologists and there is currently no contrast agent for MRI with this property available. Utilizing tumor selectivity and exceptional MRI signal strength, SpagoPix has the potential to
Radiation therapy is one of the corner stones in successful cancer treatments. External radiation is however not useful for tumors that are deeply embedded or for metastatic disease. In such cases the use of internal radionuclide therapy can provide a means for efficient treatment. The clinical use of radionuclide therapies is well-established and is expected to grow substantially with the recent approval of novel agents.
Spago Nanomedical’s therapeutic nanomaterial Tumorad consist of nanoparticles loaded with radionuclides that will passively accumulate in tumor tissue and there deliver a local and optimized radiation dose. The tumor selectivity means that the radiation to surrounding, healthy tissue can be minimized.
The key to successful treatment of many cancers is the continuous access to alternative therapies where existing therapies fail. Tumorad thus holds promise as a novel alternative tumor treatment with specific potential to
Spago Nanomedical´s strategy is to utilize our expert capabilities in chemistry and nanomedicine development to develop our projects into human clinical trials. The business model is based on outlicensing or strategic partnering with industrial actors who maintain capabilities to proceed development up to registration and commercialization. This reduces the internal need of capital as well as maximizing the potential for successful market penetration.